MALVERN, Pa. and MONTREAL--(BUSINESS WIRE)--Gemin X Pharmaceuticals, Inc. announced the discovery of the mechanism of action of GMX1777 (EB1627), a soluble, intravenously administered prodrug of the pharmacologically active compound GMX1778 (CHS828), and presented the results of preclinical data that lead to the design of the current first Phase 1 clinical trial of GMX1777. Data were presented in two poster sessions at the American Association of Cancer Research-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco.
